The National Institute of Allergy and Infectious Diseases (NIAID) has announced new contract awards to support the Phase I Clinical Trial Unit for Therapeutics Against Infectious Diseases.
Since Phase I studies are often on the critical path for product development of bacterial, viral, parasitic, and fungal countermeasures, the ability to prepare protocols and execute trials in a timely manner is important. To help meet these goals and move promising candidates into the clinical pipeline in a timely manner, DMID initially awarded contracts for the Phase I Unit in 2008.
The current contract announcement is the result of a recompete of these program requirements to continue to provide NIAID with the infrastructure necessary for the design and conduct of Phase I clinical trials for therapeutics.
Awards were made to the following organizations, with a maximum value of $90,000,000:
- Dynport Vaccine Company
- Duke University
- Clinical Research Management
The types of trials conducted or planned include first-in-human small molecule and monoclonal antibody trials, corrected QT interval (QTc) trials, and drug-drug interaction trials.
The contracts were awarded via Solicitation Number: RFP-NIAID-DMID-NIHAI2013178
